Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,021 INR | +2.26% | +2.52% | +25.86% |
Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
Sales 2024 * | 39.19B 470M | Sales 2025 * | 45.13B 541M | Capitalization | 179B 2.15B |
---|---|---|---|---|---|
Net income 2024 * | 13.95B 167M | Net income 2025 * | 16.87B 202M | EV / Sales 2024 * | 4.16 x |
Net cash position 2024 * | 15.67B 188M | Net cash position 2025 * | 31.57B 379M | EV / Sales 2025 * | 3.26 x |
P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
10.8
x | Employees | 3,946 |
Yield 2024 * |
1% | Yield 2025 * |
1.13% | Free-Float | 46.76% |
Latest transcript on NATCO Pharma Limited
1 day | +4.01% | ||
1 week | +4.28% | ||
Current month | +9.10% | ||
1 month | +8.36% | ||
3 months | +19.41% | ||
6 months | +30.13% | ||
Current year | +28.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 00-07-02 | |
Founder | 78 | 81-09-18 | |
Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 81-09-18 | |
Chief Executive Officer | 46 | 00-07-02 | |
Director/Board Member | 70 | 14-04-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +0.68% | - | |
0.00% | 34 M€ | +2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1,021 | +2.26% | 1 288 313 |
24-04-24 | 998.6 | -2.37% | 367,850 |
24-04-23 | 1,023 | +1.70% | 639,513 |
24-04-22 | 1,006 | +0.63% | 624,944 |
24-04-19 | 999.4 | +0.34% | 534,620 |
Delayed Quote NSE India S.E., April 25, 2024 at 04:28 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.02% | 2.15B | |
+25.61% | 660B | |
+24.28% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.21% | 219B | |
-9.73% | 196B | |
+6.53% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- NATCOPHARM Stock